Histologic Assessment of the Difference Between 18F-2-fluoro-2-deoxy_D-glucose Positron Emission Mammography(PEM) and Magnetic Resonance Imaging (MRI) of the Breast

Not Applicable

Terminated

• Conditions: Breast Cancer
• Interventions: Device: Positron Emission Mammography (PEM) and Magnetic Resonance Imaging (MRI)

• Registration Number: NCT01249157
• Lead Sponsor: Memorial Sloan Kettering Cancer Center

Brief Summary

Positron Emission Mammography (PEM) is a newly developed imaging examination of the breast that uses a radioactive glucose based tracer, which is a form of sugar attached to a low radiation agent, to detect cancer cells. The radioactive glucose based tracer is called fluorodeoxyglucose (FDG), and it is FDA approved. A PEM scanner is able to better detect cancer cells within the breast, more than a regular PET scanner. The PEM scanner is also FDA approved. This type of imaging may be able to see the breast cancer before it could be seen with mammograms and may be as good as or better than breast MRI.

The purpose of this study is to compare the value of FDG Positron Emission Mammography (PEM) with contrast enhanced Magnetic Resonance Imaging (MRI) of the breast for patients with breast cancer. This study will also perform special pathology test to compare the FDG PEM and contrast enhanced breast MRI images with the results from the standard of care breast surgery. This may teach us more about the biology of each breast tumor.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-11
• Study First Submitted: 2010-11-24
• Study First Submitted QC: 2010-11-24
• Study First Posted: 2010-11-29
• Primary Completion: 2012-08
• Study Completion: 2012-08
• Results First Submitted: 2015-10-17
• Status Verified: 2015-11
• Results First Submitted QC: 2015-11-19
• Last Update Submitted: 2015-11-19
• Results First Posted: 2015-12-24
• Last Update Posted: 2015-12-24

Recruitment & Eligibility

• Status: TERMINATED
• Sex: Female
• Target Recruitment: 6

Inclusion Criteria

• Female patients with recently diagnosed invasive or in situ breast cancer by core needle biopsy or FNA (confirmed at MSKCC) prior to enrollment.
• Patients planning treatment with mastectomy at MSKCC.
• Patients 21 years old or older.
• Patients who had or are having a breast MRI within 30 days or less of PEM.
• Patients who had or are having a digital mammogram.

Read More

Exclusion Criteria

• Patients who are pregnant or breast feeding.
• Patients with prior radiation therapy or endocrine therapy.
• Patients who had a prior lumpectomy.
• Patients who are diabetic.
• Patients with moderate to end stage kidney disease.
• Patients who have a contraindication to MRI (i.e. pacemaker, metallic implants, etc).

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
MRI and PEM scans	Positron Emission Mammography (PEM) and Magnetic Resonance Imaging (MRI)	All consenting patients who are to have staging breast MRI, will be offered 18FDG PEM (Positron Emission Mammography) within 30 days. If the patient had a previous breast MRI that was done within 30 days at an outside institution, this MRI can be used if a radiologist determines that it is an adequate study. The surgery date will not be affected by the additional PEM evaluation. All imaging will be done and reviewed by MSKCC breast imagers. MRI and PEM findings suggestive of malignancy will be prospectively recorded in both the ipsilateral and contralateral breast.

Primary Outcome Measures

Name	Time	Method
To Evaluate the Accuracy of Preoperative 18FDG PEM	2 years	using pathology as the gold standard and descriptively compare it to the accuracy of breast MRI in an exploratory analysis which will generate data for future studies. The first 5 patients who consent to the study were used for training purposes only.

Trial Locations

Locations (1)

Memorial Sloan Kettering Cancer Center; 🇺🇸 New York, New York, United States